Great West Life Assurance Co. Can reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.2% during the second quarter, according to its most recent filing with the SEC. The fund owned 82,338 shares of the company’s stock after selling 15,869 shares during the period. Great West Life Assurance Co. Can owned about 0.09% of IDEXX Laboratories worth $13,267,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of IDXX. Bronfman E.L. Rothschild L.P. boosted its stake in shares of IDEXX Laboratories by 2.3% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 770 shares of the company’s stock valued at $119,000 after buying an additional 17 shares during the period. Capital Advisors Ltd. LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $128,000. Acrospire Investment Management LLC boosted its stake in shares of IDEXX Laboratories by 496.5% in the first quarter. Acrospire Investment Management LLC now owns 841 shares of the company’s stock valued at $130,000 after buying an additional 700 shares during the period. Global X Management Co. LLC boosted its stake in shares of IDEXX Laboratories by 44.6% in the first quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock valued at $162,000 after buying an additional 323 shares during the period. Finally, Flagship Harbor Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the first quarter valued at approximately $200,000. Hedge funds and other institutional investors own 89.80% of the company’s stock.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at 154.77 on Wednesday. The firm’s 50-day moving average price is $163.25 and its 200 day moving average price is $154.39. IDEXX Laboratories, Inc. has a 12-month low of $102.45 and a 12-month high of $173.01. The firm has a market cap of $13.51 billion, a P/E ratio of 53.24 and a beta of 0.49.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The firm had revenue of $508.90 million for the quarter, compared to analysts’ expectations of $502.44 million. During the same quarter last year, the business earned $0.74 earnings per share. The company’s revenue was up 9.1% compared to the same quarter last year. On average, equities analysts expect that IDEXX Laboratories, Inc. will post $3.17 earnings per share for the current fiscal year.

IDEXX Laboratories announced that its board has approved a share buyback program on Wednesday, May 3rd that allows the company to buyback 3,000,000 outstanding shares. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/09/idexx-laboratories-inc-idxx-shares-sold-by-great-west-life-assurance-co-can.html.

IDXX has been the topic of several research reports. BidaskClub cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Canaccord Genuity reiterated a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, June 13th. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $177.00 price target on the stock in a research report on Tuesday, June 13th. Finally, Stifel Nicolaus boosted their price target on shares of IDEXX Laboratories from $150.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday, May 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $173.80.

In other IDEXX Laboratories news, Director Lawrence D. Kingsley purchased 2,000 shares of the company’s stock in a transaction dated Thursday, August 3rd. The shares were bought at an average price of $151.76 per share, with a total value of $303,520.00. Following the completion of the transaction, the director now directly owns 3,344 shares in the company, valued at approximately $507,485.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William T. End sold 5,000 shares of the firm’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $162.55, for a total value of $812,750.00. Following the sale, the director now directly owns 45,256 shares in the company, valued at approximately $7,356,362.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,572 shares of company stock worth $3,423,677. 2.77% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.